Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report.
Brice LeyratXavier DurandoCéleste PinardMaureen BernadachPublished in: OncoTargets and therapy (2021)
We report here the original case of a patient presenting a lung adenocarcinoma with an intron 14 mutation and having a durable TKI response.